The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...
Pharmaceutical Technology on MSN
Parkinson’s research reaches pivotal stage, but barriers remain
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results